Oseltamivir blocks human neuronal nicotinic acetylcholine receptor-mediated currents

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 2, 2015, Pages 87-95

  Muraki, Katsuhiko ^a   Hatano, Noriyuki ^a   Suzuki, Hiroka ^a   Muraki, Yukiko ^a   Iwajima, Yui ^b   Maeda, Yasuhiro ^b   Ono, Hideki ^b,c  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c MUSASHINO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; NICOTINIC AGENT; NICOTINIC RECEPTOR; OSELTAMIVIR; ACETYLCHOLINE; ANTIVIRUS AGENT; NICOTINE; NICOTINIC RECEPTOR ALPHA3BETA4;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METABOLITE; NERVE CELL; NERVE CELL NETWORK; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHOLE CELL PATCH CLAMP; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; NEUROBLASTOMA; PATCH CLAMP TECHNIQUE; TUMOR CELL LINE;

ACETYLCHOLINE; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; NEUROBLASTOMA; NEURONS; NICOTINE; NICOTINIC AGONISTS; OSELTAMIVIR; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC;

EID: 84921386128     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12290     Document Type: Article

References (29)

1. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42:647-53.
2. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998;37:107-20.
3. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006;319:1477-84.
4. Kadowaki T, Komagamine T, Suzuki K, Hirata K. Oseltamivir-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2011;17:133-4.
5. Chung S, Joung YS. Oseltamivir (tamiflu) induced depressive episode in a female adolescent. Psychiatry Investig 2010;7:302-4.
6. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill 2009;14:19287.
7. Jefferson T, Jones M, Doshi P, Del Mar C. Possible harms of oseltamivir-a call for urgent action. Lancet 2009;374:1312-3.
8. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother 2010;65(Suppl 2):ii11-24.
9. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-50.
10. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016-24.
11. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-33.
12. Ono H, Iwajima Y, Nagano Y, Chazono K, Maeda Y, Ohsawa M et al. Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice. Basic Clin Pharmacol Toxicol 2013;113:25-30.
13. Ono H, Nagano Y, Matsunami N, Sugiyama S, Yamamoto S, Tanabe M. Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice. Biol Pharm Bull 2008;31:638-42.
14. Freichel C, Breidenbach A, Hoffmann G, Korner A, Gatti S, Donner B et al. Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat. Basic Clin Pharmacol Toxicol 2012;111:50-7.
15. Hiasa M, Isoda Y, Kishimoto Y, Saitoh K, Kimura Y, Kanai M et al. Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir. Br J Pharmacol 2013;169:115-29.
16. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89:73-120.
17. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006;27:482-91.
18. Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 2010;628:6-10.
19. Hatano N, Itoh Y, Suzuki H, Muraki Y, Hayashi H, Onozaki K et al. Hypoxia-inducible factor-1alpha (HIF1alpha) switches on transient receptor potential ankyrin repeat 1 (TRPA1) gene expression via a hypoxia response element-like motif to modulate cytokine release. J Biol Chem 2012;287:31962-72.
20. Nelson ME, Lindstrom J. Single channel properties of human α3 AChRs: impact of β2, β4 and α5 subunits. J Physiol 1999;516(Pt 3):657-78.
21. Nelson ME, Wang F, Kuryatov A, Choi CH, Gerzanich V, Lindstrom J. Functional properties of human nicotinic AChRs expressed by IMR-32 neuroblastoma cells resemble those of α3β4 AChRs expressed in permanently transfected HEK cells. J Gen Physiol 2001;118:563-82.
22. 2+ permeation of stably transfected α3/β4 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1999;55:970-81.
23. Francis MM, Vazquez RW, Papke RL, Oswald RE. Subtype-selective inhibition of neuronal nicotinic acetylcholine receptors by cocaine is determined by the α4 and β4 subunits. Mol Pharmacol 2000;58:109-19.
24. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295:321-7.
25. De Biasi M. Nicotinic mechanisms in the autonomic control of organ systems. J Neurobiol 2002;53:568-79.
26. Puttfarcken PS, Manelli AM, Arneric SP, Donnelly-Roberts DL. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells. J Neurochem 1997;69:930-8.
27. Sun M, Lee CJ, Shin HS. Reduced nicotinic receptor function in sympathetic ganglia is responsible for the hypothermia in the acetylcholinesterase knockout mouse. J Physiol 2007;578:751-64.
28. Morrison SF, Nakamura K, Madden CJ. Central control of thermogenesis in mammals. Exp Physiol 2008;93:773-97.
29. Nakamura Y, Nakamura K, Matsumura K, Kobayashi S, Kaneko T, Morrison SF. Direct pyrogenic input from prostaglandin EP3 receptor-expressing preoptic neurons to the dorsomedial hypothalamus. Eur J Neurosci 2005;22:3137-46.